Improving the quality of life in patients with chronic obstructive pulmonary disease: focus on indacaterol

Figures & data

Table 1 Pivotal trials of 12 weeks in duration or longer

Reference	Study	Severity of COPD	Study duration (weeks)	Treatment arms
Feldman et al^Citation13	B2346, INLIGHT1	Moderate to severe	12	IND 150 μg (n = 211) Placebo (n = 205)
Kornmann et al^Citation14	B2336, INLIGHT2	Moderate to severe	26	IND 150 μg (n = 330) SAL 50 μg BID (n = 334) Placebo (n = 335)
Dahl et al^Citation15	B2334, INVOLVE	Moderate to severe	52	IND 300 (n = 437) or 600 μg (n = 428) FOR 12 μg BID (n = 435) Placebo (n = 432)
Donohue et al^Citation16	B2335S, INHANCE	Moderate to severe	26	IND 150 (n = 416) or 300 μg (n = 416) Placebo (n = 418) Open-label TIO 18 μg (n = 415)
Buhl et al^Citation17	B2350, INTENSITY	Moderate to severe	12	IND 150 μg (n = 794) TIO 18 μg (n = 799)
Korn et al^Citation18	B2349, INSIST	Moderate to severe	12	IND 150 μg (n = 559) SAL 50 μg BID (n = 562)
Chapman et al^Citation19	Study 2335SE, INDORSE (extension of INHANCE)	Moderate to severe	Additional 26 (total 52)	IND 150 or 300 μg Placebo (n = 415)

Abbreviations: BID, twice daily; COPD, chronic obstructive pulmonary disease; FOR, formoterol; IND, indacaterol; SAL, salmeterol; TIO, tiotropium.

Figure 1 Effect of treatment on use of as-needed salbutamol, averaged over the period of the studies, as percentage of days without use of salbutamol.

FeldmanGSilerTPrasadNINLIGHT-1study groupEfficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week studyBMC Pulm Med2010101120211002

 PubMed Web of Science ®Google Scholar

KornmannODahlRCentanniSINLIGHT-2 study investigatorsOnce-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparisonEur Respir J201137227327920693243

 PubMed Web of Science ®Google Scholar

DahlRChungKFBuhlRINVOLVE study investigatorsEfficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPDThorax201065647347920522841

 PubMed Web of Science ®Google Scholar

DonohueJFFogartyCLötvallJHANCE study investigatorsOnce-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropiumAm J Respir Crit Care Med2010182215516220463178

 PubMed Web of Science ®Google Scholar

BuhlRDunnLJDisdierCINTENSITY study investigatorsBlinded 12-week comparison of once-daily indacaterol and tiotropium in COPDEur Respir J201138479780321622587

 PubMed Web of Science ®Google Scholar

KornSKerwinEAtisSAmosCOwenRLassenCINSIST study groupIndacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week studyRespir Med2011105571972621367594

 PubMed Web of Science ®Google Scholar

ChapmanKRRennardSIDograAOwenRLassenCKramerBINDORSE study investigatorsLong-term safety and efficacy of indacaterol, a long-acting β2-agonist, in subjects with COPD: a randomized, placebo-controlled studyChest20111401687521349928

 PubMed Web of Science ®Google Scholar